Jennifer's mailing address filed with the SEC is C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK, IL, 60010-7208.
Over the last 6 years, insiders at Eton Pharmaceuticals have traded over $20,773,599 worth of Eton Pharmaceuticals stock and bought 488,500 units worth $3,287,585 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum et Health, Inc. Harrow. On average, Eton Pharmaceuticals executives and independent directors trade stock every 61 days with the average trade being worth of $746,905. The most recent stock trade was executed by Sean Brynjelsen on 22 September 2022, trading 10,000 units of ETON stock currently worth $21,000.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals executives and other stock owners filed with the SEC include: